Format

Send to

Choose Destination
Bull Exp Biol Med. 2014 Jul;157(3):344-9. doi: 10.1007/s10517-014-2562-5.

Noopept normalizes parameters of the incretin system in rats with experimental diabetes.

Author information

1
V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences, Moscow, Russia, rita.ostrovskaya@gmail.com.

Abstract

Experiments on adult Wistar rats with streptozotocin-induced diabetes showed that antihyperglycemic activity of an original nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is more pronounced under conditions of oral application than after intraperitoneal injection. These data provided a basis for studying the effect of Noopept on major indexes of the incretin system. Streptozotocin was shown to decrease the concentrations of incretin GLP-1 and insulin in the blood. Noopept had a normalizing effect on these parameters. This influence of Noopept was not related to the inhibition of a major enzyme metabolizing incretins (dipeptidyl peptidase IV). A reference drug sitagliptin also increased the contents of incretins and insulin, which was associated with the inhibition of dipeptidyl peptidase IV. It is known that GLP-1 increases NGF expression in the insular system. Our results suggest that the increase in incretin activity contributes to the antiapoptotic effect of Noopept on pancreatic β cells. The mechanism for an increase in blood GLP-1 level after oral application of Noopept requires further investigations.

PMID:
25065315
DOI:
10.1007/s10517-014-2562-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center